Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 106

    1.

    Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report.

    Mesía R, Palmero R, Cos M, Vilajosana E, Vázquez S.

    Head Neck Oncol. 2010 Jan 27;2:3.

    PMID:
    20181021
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Platinum-based chemotherapy plus cetuximab in head and neck cancer.

    Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R.

    N Engl J Med. 2008 Sep 11;359(11):1116-27.

    PMID:
    18784101
    [PubMed - indexed for MEDLINE]
    Free Article
    3.

    Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.

    Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R, Gascón P, Amellal N, Harstrick A, Eckardt A.

    J Clin Oncol. 2005 Aug 20;23(24):5568-77. Epub 2005 Jul 11.

    PMID:
    16009950
    [PubMed - indexed for MEDLINE]
    4.

    Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.

    Mesía R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H, Cupissol D, De Raucourt D, Benasso M, Koralewski P, Delord JP, Bokemeyer C, Curran D, Gross A, Vermorken JB.

    Ann Oncol. 2010 Oct;21(10):1967-73. Epub 2010 Mar 24.

    PMID:
    20335368
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    5.

    Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

    Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C, Humblet Y, Lopez-Pousa A, Hitt R, Vega Villegas ME, Duck L, Rosine D, Amellal N, Schueler A, Harstrick A.

    J Clin Oncol. 2006 Jun 20;24(18):2866-72. Epub 2006 May 22.

    PMID:
    16717293
    [PubMed - indexed for MEDLINE]
    6.

    Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.

    Rivera F, García-Castaño A, Vega N, Vega-Villegas ME, Gutiérrez-Sanz L.

    Expert Rev Anticancer Ther. 2009 Oct;9(10):1421-8.

    PMID:
    19828002
    [PubMed - indexed for MEDLINE]
    7.

    Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.

    Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J.

    Cancer. 2008 Jun 15;112(12):2710-9.

    PMID:
    18481809
    [PubMed - indexed for MEDLINE]
    Free Article
    8.

    Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.

    Frampton JE.

    Drugs. 2010 Oct 22;70(15):1987-2010. doi: 10.2165/11205010-000000000-00000. Review.

    PMID:
    20883055
    [PubMed - indexed for MEDLINE]
    9.

    Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.

    Bernier J.

    Nat Clin Pract Oncol. 2008 Dec;5(12):705-13. Epub 2008 Sep 30. Review.

    PMID:
    18825142
    [PubMed - indexed for MEDLINE]
    10.

    Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.

    Licitra L, Mesia R, Rivera F, Remenár E, Hitt R, Erfán J, Rottey S, Kawecki A, Zabolotnyy D, Benasso M, Störkel S, Senger S, Stroh C, Vermorken JB.

    Ann Oncol. 2011 May;22(5):1078-87. Epub 2010 Nov 3.

    PMID:
    21048039
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    11.

    Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.

    Greenhalgh J, Bagust A, Boland A, Fleeman N, McLeod C, Dundar Y, Proudlove C, Shaw R.

    Health Technol Assess. 2009 Oct;13 Suppl 3:49-54. Review.

    PMID:
    19846029
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.

    Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS.

    J Clin Oncol. 2005 Aug 20;23(24):5578-87. Epub 2005 Jul 11.

    PMID:
    16009949
    [PubMed - indexed for MEDLINE]
    13.

    Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.

    Bagust A, Greenhalgh J, Boland A, Fleeman N, McLeod C, Dickson R, Dundar Y, Proudlove C, Shaw R.

    Pharmacoeconomics. 2010;28(6):439-48. doi: 10.2165/11532220-000000000-00000. Review.

    PMID:
    20465313
    [PubMed - indexed for MEDLINE]
    14.

    Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer.

    Blick SK, Scott LJ.

    Drugs. 2007;67(17):2585-607. Review.

    PMID:
    18034592
    [PubMed - indexed for MEDLINE]
    15.

    Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

    Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA; Eastern Cooperative Oncology Group.

    J Clin Oncol. 2005 Dec 1;23(34):8646-54. Erratum in: J Clin Oncol. 2006 Feb 1;24(4):724.

    PMID:
    16314626
    [PubMed - indexed for MEDLINE]
    16.

    Cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma: experience from an area in which betel nut chewing is popular.

    Chang PM, Hsieh YY, Chen MH, Tzeng CH, Chu PY, Chang SY, Chen PM, Yang MH.

    J Chin Med Assoc. 2010 Jun;73(6):292-9.

    PMID:
    20603086
    [PubMed - indexed for MEDLINE]
    17.

    Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.

    Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J.

    J Clin Oncol. 2007 Jun 1;25(16):2171-7.

    PMID:
    17538161
    [PubMed - indexed for MEDLINE]
    18.

    Cetuximab in the treatment of squamous cell carcinoma of the head and neck.

    Specenier P, Vermorken JB.

    Expert Rev Anticancer Ther. 2011 Apr;11(4):511-24. Review.

    PMID:
    21504318
    [PubMed - indexed for MEDLINE]
    19.

    Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).

    Galetta D, Giotta F, Rosati G, Gebbia V, Manzione L, Di Bisceglie M, Borsellino N, Colucci G.

    Anticancer Res. 2005 Nov-Dec;25(6C):4445-9.

    PMID:
    16334124
    [PubMed - indexed for MEDLINE]
    20.

    Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.

    Kiyota N, Tahara M, Kadowaki S, Fuse N, Doi T, Minami H, Ohtsu A.

    Jpn J Clin Oncol. 2009 Apr;39(4):225-30. Epub 2009 Feb 10.

    PMID:
    19211574
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk